VALERIO TX (ALVIO.PA) Stock Price & Overview
EPA:ALVIO • FR0010095596
The current stock price of ALVIO.PA is 0.1355 EUR. Today ALVIO.PA is down by -0.37%. In the past month the price decreased by -10.86%. In the past year, price increased by 162.6%.
ALVIO.PA Key Statistics
- Market Cap
- 67.675M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.09
- Dividend Yield
- N/A
ALVIO.PA Stock Performance
ALVIO.PA Stock Chart
ALVIO.PA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to ALVIO.PA. When comparing the yearly performance of all stocks, ALVIO.PA is one of the better performing stocks in the market, outperforming 97.85% of all stocks.
ALVIO.PA Earnings
ALVIO.PA Forecast & Estimates
ALVIO.PA Groups
Sector & Classification
ALVIO.PA Financial Highlights
Over the last trailing twelve months ALVIO.PA reported a non-GAAP Earnings per Share(EPS) of -0.09. The EPS increased by 27.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -64.42% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ALVIO.PA Ownership
ALVIO.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 25.5 | 38.133B | ||
| ARGX | ARGENX SE | 25.4 | 38.12B | ||
| 22UA | BIONTECH SE-ADR | N/A | 18.515B | ||
| ABVX | ABIVAX SA | N/A | 8.129B | ||
| 2X1 | ABIVAX SA | N/A | 8.097B | ||
| GXE | GALAPAGOS NV | N/A | 1.831B | ||
| GLPG | GALAPAGOS NV | N/A | 1.827B | ||
| NANO | NANOBIOTIX | N/A | 1.328B | ||
| IVA | INVENTIVA SA | N/A | 1.098B | ||
| 6IV | INVENTIVA SA | N/A | 1.098B | ||
| PHIL | PHILOGEN SPA | 18.09 | 663.748M | ||
| XUP | GENFIT | N/A | 468.027M | ||
| GNFT | GENFIT | 831.37 | 435.275M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About ALVIO.PA
Company Profile
Valerio Therapeutics SA is a is a clinical-stage biotechnology company, which engages in the development of oncology drugs targeting tumor intracellular processes. The company is headquartered in Paris, Ile-De-France and currently employs 25 full-time employees. The company went IPO on 2005-07-12. The firm targets tumor DNA functions through unparalleled mechanisms of action in the sought-after field of DNA damage response (DDR). The company aims at holding a portfolio of advanced programs targeting severe pathologies with unmet clinical needs. The company has two programs in clinical development stage: Livatag, a doxorubicin Transdrag in Phase III, for the treatment of primary liver cancer, and Validive, a clonidine Lauriad in Phase II, for treatment of radio/chemo-induced severe oral mucositis at patients with head and neck cancer. The company also has one registered product in the United States, Beleodaq/ belinostat, for the treatment of peripheral T-Cell lymphoma (PTCL) and opportunities for further development; and two initial drugs registered in Europe and the United States: Loramyc/ Oravig for the treatment of oropharyngeal candidiasis, and Sitavig for the treatment of recurring herpes labialis.
Company Info
IPO: 2005-07-12
VALERIO TX
49 boulevard du General Martial Valin
Paris ILE-DE-FRANCE FR
Employees: 25
Phone: 33145587600
VALERIO TX / ALVIO.PA FAQ
What does VALERIO TX do?
Valerio Therapeutics SA is a is a clinical-stage biotechnology company, which engages in the development of oncology drugs targeting tumor intracellular processes. The company is headquartered in Paris, Ile-De-France and currently employs 25 full-time employees. The company went IPO on 2005-07-12. The firm targets tumor DNA functions through unparalleled mechanisms of action in the sought-after field of DNA damage response (DDR). The company aims at holding a portfolio of advanced programs targeting severe pathologies with unmet clinical needs. The company has two programs in clinical development stage: Livatag, a doxorubicin Transdrag in Phase III, for the treatment of primary liver cancer, and Validive, a clonidine Lauriad in Phase II, for treatment of radio/chemo-induced severe oral mucositis at patients with head and neck cancer. The company also has one registered product in the United States, Beleodaq/ belinostat, for the treatment of peripheral T-Cell lymphoma (PTCL) and opportunities for further development; and two initial drugs registered in Europe and the United States: Loramyc/ Oravig for the treatment of oropharyngeal candidiasis, and Sitavig for the treatment of recurring herpes labialis.
What is the current price of ALVIO stock?
The current stock price of ALVIO.PA is 0.1355 EUR. The price decreased by -0.37% in the last trading session.
Does VALERIO TX pay dividends?
ALVIO.PA does not pay a dividend.
What is the ChartMill technical and fundamental rating of ALVIO stock?
ALVIO.PA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
On which exchange is ALVIO.PA stock listed?
ALVIO.PA stock is listed on the Euronext Paris exchange.